Secukinumab (anti-IL-17A)

目录号：A2025         批次号: A202501

打印

Secukinumab (anti-IL-17A) (Cosentyx, AIN457) 是人IgG1κ单克隆抗体，与蛋白 interleukin (IL)-17A 结合，可用于治疗牛皮癣、强直性脊柱炎和银屑病关节炎等。MW=147.9 kDa。

抗体信息

CAS号 1229022-83-6
配制 PBS buffer, pH 7.2
推荐同型对照 Human IgG1
来源 Human
储存条件
(自收到货起)		 Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles
除菌 0.2 μM filtered
纯度 99.82%
蛋白浓度 5.00mg/ml
内毒素 <1EU/mg

Secukinumab (anti-IL-17A)在文献中得到引用

Interleukin-17 regulates keratinocyte proliferation in psoriasis through the MALAT1/miR-125b/BRD4 axis [ American Scientific Publishers, 2024, 174-182(9)] PubMed: None
Overexpression of microRNA-145 enhanced docetaxel sensitivity in breast cancer cells via inactivation of protein kinase B gamma-mediated phosphoinositide 3-kinase -protein kinase B pathway [ Signal Transduct Target Ther, 2022, 7(1):80] PubMed: 35301282
Hepatic interferon regulatory factor 8 expression mediates liver ischemia/reperfusion injury in mice [ Biochem Pharmacol, 2021, 192:114728] PubMed: 34400126

禁止用于人体及治疗！